- Analytica Investor
- Posts
- Can Seres Therapeutics Be a Breakout Biotech by 2026?
Can Seres Therapeutics Be a Breakout Biotech by 2026?
After divesting its only commercial product, Seres Therapeutics is making a bold bet on its pipeline. Here's why that gamble might pay off.
Matthias Schneider
November 23, 2025
Welcome Investors!
Seres Therapeutics (NASDAQ: MCRB) has been through a transformation. After launching the first FDA-approved oral microbiome therapy (VOWST), Seres handed off that asset to Nestlé in 2024.
In doing so, $MCRB ( ▼ 4.69% ) walked away from short-term revenue but freed itself from commercial burdens, wiped its debt clean, and refocused entirely on clinical innovation.
Now, with its flagship drug candidate SER-155, Seres is aiming to redefine infection prevention in immunocompromised patients.
For investors, the key question is: can Seres pull it off?
Matthias Schneider
Editor at Analytica Investor